# Medtronic Plc (MDT) stock news and updates

As of November 19, 2026. Source: https://www.clearthesis.ai/updates/MDT

## Our view on the Medtronic Plc investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/MDT

## Latest updates on Medtronic Plc

### Hugo robotic surgery system cleared for general surgery in the U.S.

*November 17, 2026 · product · significance: major · signal: positive*

The U.S. Food and Drug Administration (FDA) has cleared the Hugo robotic-assisted surgery system for use in general surgery. This is a major step forward because it allows Medtronic to compete in one of the busiest and fastest-growing areas of the surgical market, rather than being limited to more specialized procedures. Winning in robotics is a core part of the company's plan to speed up its growth. For years, this market has been led by a single large rival, and getting Hugo into U.S. operating rooms for common general surgeries is the best chance Medtronic has to take meaningful market share. If the system is well-received by surgeons, it should help drive higher-margin revenue for years to come.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/medtronic-announces-fda-clearance-of-general-surgery-procedures-for-the-hugo-robotic-assisted-surgery-ras-system-302941366.html)

### Medtronic to acquire Contego Medical for carotid artery treatments

*November 16, 2026 · news · significance: notable · signal: positive*

Medtronic is moving to acquire Contego Medical, a private firm that makes devices to treat carotid artery disease. The two companies have worked together since early 2025, when Medtronic began selling Contego's specialized filter system that helps prevent strokes during medical procedures. By buying the company outright, Medtronic gains full control over this technology and its future versions. This is a targeted move to strengthen the cardiovascular business, which is one of the company's largest and most stable divisions. While the price was not disclosed, bringing this technology in-house suggests Medtronic sees enough long-term demand for these specialized filters to justify owning the manufacturing and development rather than just acting as a distributor.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/medtronic-to-acquire-contego-medical-expanding-access-to-next-generation-carotid-therapies-302939849.html)

### Quarterly earnings expected on November 24

*November 13, 2026 · earnings · significance: minor · signal: neutral*

Medtronic is scheduled to report its quarterly results on Tuesday, November 24. Analysts expect the company to earn about $1.33 per share on revenue of roughly $9.48 billion. This will be an important check on whether the company is maintaining its recent growth streak, having topped analyst expectations in each of the last eight quarters. Beyond the headline numbers, it is worth watching for updates on the Hugo robotic surgery system and the diabetes business. These high-tech areas are central to the company's plan to move from a slow-growing maker of traditional medical devices into a faster-growing technology leader.

### FDA approves updated labeling for Medtronic blood pressure procedure

*November 4, 2026 · news · significance: notable · signal: positive*

Medtronic received FDA approval to update the labeling for its Symplicity Spyral system, a procedure that uses radio waves to calm overactive nerves near the kidneys and lower blood pressure. The update is backed by a study showing that nearly nine out of 10 patients saw a clinical benefit six months after the procedure. This is a win for one of the company's newer growth areas. By adding this real-world data to the official label, Medtronic makes it easier for doctors to choose this treatment over traditional daily pills for patients with high blood pressure. While it is still a small part of the overall business, proving the long-term success of these specialized procedures is key to the company's shift toward higher-tech, higher-margin products.

Sources: [PRNewsWire](https://www.prnewswire.com/news-releases/tct26-medtronic-symplicity-blood-pressure-procedure-shows-significant-blood-pressure-drops-in-spyral-affirm-real-world-study-302928326.html)

### Partner Orchestra BioMed to present data on new artery treatment

*October 30, 2026 · news · significance: minor · signal: neutral*

Orchestra BioMed, a company Medtronic partners with, will present data on its Virtue SAB device at an upcoming medical conference. The device is designed to treat narrowed arteries by infusing a liquid medicine directly into the vessel wall, which aims to keep the artery open longer than traditional stents or coated balloons. Medtronic has an exclusive right to distribute this technology if it is eventually approved. While this specific presentation is a routine update on the device's mechanism, the partnership is part of Medtronic's broader effort to find new ways to grow its heart and vascular business as older products face more competition.

Sources: [GlobeNewsWire](https://www.globenewswire.com/news-release/2026/10/29/3391276/0/en/orchestra-biomed-announces-virtue-sab-presentation-at-tct-2026.html)

## Medtronic Plc earnings

In Q1 2027, reported on September 1, 2026, Medtronic Plc posted earnings of $1.45 per share against $1.39 expected, and revenue of $9.8 billion against $9.5 billion expected.

The next earnings report is expected on November 24, 2026. Analysts expect $1.33 per share. Revenue is expected around $9.5 billion.

What to watch: Whether diabetes segment growth stays above 10 percent, which would prove the business is still winning customers after its recent spin-off.

## Recent analyst activity on MDT

- November 17, 2026: TD Cowen Set target. Price target: $110.00.
- November 17, 2026: Piper Sandler Set target. Price target: $120.00.

## What's ahead for Medtronic Plc

- November 24, 2026: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/MDT
